| Similar Articles |
|---|
 |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short.   |
Bio-IT World
May 2006
Mark D. Uehling |
Bio-IT World CTMS Survey An online survey of the clinical trial management system market reveals some divergences between how the pharma/biotech folks and the contract research folks see the CTMS landscape. Are our respondents happy with the CTMS landscape? |
Bio-IT World
July 11, 2002
Michael Swenson |
The End of Relational Databases? Until now, the use of relational databases within genomics and proteomics was treated as a given, with no one prepared to question whether this was an appropriate use of technology. That may be about to change. |
| Knowledge@Wharton |
A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies... |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
Bio-IT World
June 12, 2002
Morris R. Levitt |
A New Economic Paradigm for Bio-IT? All who work in the bio-IT industry -- scientists, IT and informatics managers, and executives -- have been aware for some time that we seem to be suspended between an acute sense of crisis and a field of boundless opportunity. |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Bio-IT World
September 16, 2004
Paul King |
Growing Gains When it comes to information technology requirements, the biotech industry is unlike any other. A key enabler of efficient and effective growth is the adoption of IT strategies specific to each of four key stages. |
Bio-IT World
March 8, 2005
Michael A. Greeley |
What's New at Big Blue? The scale of computing has improved dramatically in the life sciences. But has the bio-IT industry over-promised, and does it risk under-delivering? Ultimately, customers will want to see a return on these investments, and that won't happen in two to three years. |
Pharmaceutical Executive
May 1, 2009 |
The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. |
Bio-IT World
July 11, 2002
Mike Fitzgerald |
Funding the Future Investor G. Steven Burrill, CEO of Burrill & Company, helps biotech companies fulfill their potential. He talked recently about his view of the bio-IT field. |
Pharmaceutical Executive
July 1, 2005
Ellen H. Julian |
What Pharma Wants From IT Today Indications that compliance and productivity issues reign over information technology (IT) budgets at pharma companies were verified in the 2005 Pharmaceutical Executive/Life Science Insights Information Technology Survey of nearly 850 US pharma companies. |
The Motley Fool
April 5, 2011
Frank Vinluan |
Tranzyme Pharma's Public Offering Raises $48M, but IPO Has Little Bounce Tranzyme Pharma likely had hopes for an opening bounce on the day the drug development company went public, but that ball fell flat. |
Bio-IT World
September 11, 2003 |
Show Me the Evidence ... Some emerging bio-IT services companies are beginning to attract venture capital. |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
Pharmaceutical Executive
April 1, 2007
Walter Armstrong |
Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom. |
Bio-IT World
June 2006
Michael A. Greeley |
Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
The Motley Fool
July 22, 2004
Brian Gorman |
Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
Bio-IT World
November 2005
Charles Firneno |
The Information Value Chain By looking at the evolution of pharma's information networks, strategies can be designed for IT solutions such as CRM, CTMS, AERSs, and business analytics software to deliver the highest possible value. |
Bio-IT World
December 10, 2002
Malorye Branca |
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D. |
Bio-IT World
March 10, 2003
Mark D. Uehling |
Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together. |
Bio-IT World
June 15, 2003
Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry |
Knowledge@Wharton
October 8, 2003 |
Biosciences: High Risk, High Reward, and the Potential for "Real Chaos" While bioscience researchers struggle to understand the workings of the human body, biotech managers and investors are searching for ways to better understand this complex and quickly evolving industry, according to Wharton faculty and lecturers. |
Pharmaceutical Executive
October 1, 2005
Mark J. Ahn |
It's All Academic: Biotechs Looking to Universities Pharmaceuticals and academic institutions are forming alliances at an increasing rate to exploit the promise of emerging biological insights. |
Bio-IT World
June 15, 2003
Barash & Squires |
Hunters or Browsers? Ethnography in Bio-IT Ethnographers look at cultural clues for improved Bio-IT. |
Pharmaceutical Executive
February 1, 2009
David Johnson |
Dive into Digital Exclusive Pharma Exec survey details how pharma can make virtual channels effective marketing vehicles. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
The Motley Fool
March 30, 2005
Stephen D. Simpson |
Clinical Trials Cost Biotechs More The failure of edifoligide means little to Bristol-Myers, but a great deal to Corgentech. In the grand scheme of things, there's not much new here -- the large, well-stocked pharmaceutical goes on its way, and the biotech stock gets pummeled. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Bio-IT World
October 14, 2004
Michael Greeley |
Go East Business is great in China, and the government is strongly encouraging the local biotech industry. |
Information Today
November 29, 2004
Paula J. Hane |
Thomson Announces New Pharma Research Tool The Thomson Corp. is using the Online Information exhibition in London for the official launch of its new integrated research tool for the pharmaceutical and biotech industries. |
Bio-IT World
April 2006
Laura Huckabee-Jennings |
Southern Emergence Why Huntsville, Alabama, will be the next biotech hotbed. |
Fast Company
February 2009
Elizabeth Svoboda |
Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits. |
BusinessWeek
November 10, 2003
Arlene Weintraub |
Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk |
Pharmaceutical Executive
December 1, 2013
Peter Young |
2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great." |
Pharmaceutical Executive
January 1, 2009
Stan Bernard |
Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms. |
The Motley Fool
August 26, 2010
Travers & Jayson |
Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing? |
Bio-IT World
December 10, 2002
Jim Hall |
21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives. |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Dendreon Burn You? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. Don't start with the science; ignore the sexy story, and look at the cold, hard cash. How does Dendreon stack up? |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
